Table 1.
Summary of published trials providing information on drugs, inclusion setting criteria, number of patients, efficacy, and survival results
| Konstantinopoulos et al.43 | Drew et al.48, 49 | Zimmer et al.50 | Lee et al.51 | Liu et al.52 | Freyer et al.53 | |
|---|---|---|---|---|---|---|
| Phase | I–II | I–II | I | II | II | II |
| Drug | Pembrolizumab + niraparib | Durvalumab + olaparib ± bevacizumab | Durvalumab + olaparib ± cediranib | Durvalumab + olaparib | Dostarlimab + niraparib + bevacizumab | Durvalumab + olaparib + bevacizumab |
| Setting | Patients with advanced or metastatic triple-negative breast cancer or recurrent ovarian cancer (KEYNOTE-162) | Patients with gBRCAwt ROC and had progressed after receiving one or two prior lines of platinum-based chemotherapy (MEDIOLA) | Patients with a diagnosis of non-small-cell lung cancer, TNBC, ovarian cancer, and metastatic castrate-resistant prostate cancer | Patients with ROC who have received at least two prior regimens or who are platinum resistant or refractory during or after a first platinum containing regimen (OvCA) | Patients with platinum-resistant epithelial ROC or recurrent carcinosarcoma of the ovary, after one or two lines of standard chemotherapy (OPAL) | Patients with platinum-resistant and platinum-sensitive ROC, regardless the number of previous lines of therapy (GINECO BOLD) |
| Patients enrolled (n) | 62 (ROC) | 32 (doublet) + 31 (triplet) | Nine patients with ovarian cancer, primary peritoneal cancer, endometrial carcinoma, and TNBC received triplet therapy | 35 | 41 | 74 (41 in the platinum-resistant cohort; + 33 in the platinum-sensitive cohort) |
| Median age (range), years | 60 (46-83) | 68.5 (doublet) + 64.0 (triplet) | 59 (44-73) | 67 (40-85) | 66 (37-83) | 66 (38-89) (PlR) 65 (49-81) (PlS) |
| PFS months (95% CI) | 3.4 (2.1-5.1) | 5.5 (3.6-7.5) versus 14.7 (10.0-18.1) | — | — | 7.6 (4.2-10.6) | 4.1 (3.5-5.9) (PlR)a 4.9 (2.9-7.0) (PlS)a |
| OS months (95% CI) | — | — | — | — | — | 18.8 (9.6-NR) (PlR)a 18.5 (15.6-NR) (PlS)a |
| ORR (%) | 18 | 34.4 versus 87.1 | 44 | 15 | 17.9 | — |
| Best response | CR | CR | PR | PR | PR | — |
| DOR | NR in patients with CR or PR | 6.9 versus 11.1 | 8.5 (7-26) | — | — | — |
CI, confidence interval; CR, complete response; DOR, duration of response; gBRCAwt, germinal BRCA wild type; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; ROC, recurrent ovarian cancer; TNBC, triple-negative breast cancer.
a
Calculated as 90% CI.